Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

65.79
-4.8800-6.91%
Post-market: 66.500.7100+1.08%19:49 EDT
Volume:5.11M
Turnover:342.43M
Market Cap:9.27B
PE:-28.81
High:71.93
Open:70.41
Low:64.50
Close:70.67
52wk High:95.49
52wk Low:28.48
Shares:140.86M
Float Shares:122.00M
Volume Ratio:2.18
T/O Rate:4.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2838
EPS(LYR):-0.0122
ROE:-55.21%
ROA:-8.10%
PB:19.91
PE(LYR):-5,395.72

Loading ...

NASDAQ Net Change Percentage Gainers & Losers

Dow Jones
·
Jul 23

Sector Update: Healthcare Stocks Softer Late Afternoon

MT Newswires Live
·
Jul 23

Arrowhead Pharmaceuticals is Maintained at Buy by Chardan Capital

Dow Jones
·
Jul 23

Top Midday Gainers

MT Newswires Live
·
Jul 23

Arrowhead Pharma Shares Rise After Positive Results for Triglyceride Drug Plozasiran Trials

Dow Jones
·
Jul 23

Arrowhead price target raised to $115 from $90 at Chardan

TIPRANKS
·
Jul 23

Arrowhead Pharmaceuticals (ARWR) Stock Soars on Strong Phase 3 Trial Results

TIPRANKS
·
Jul 23

Arrowhead rises 23.4%

TIPRANKS
·
Jul 23

Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Otsuka Holdings Co (OTSKY)

TIPRANKS
·
Jul 22

U.S. Stocks on the Move-ge Vernova, Arrowhead Pharma

Reuters
·
Jul 22

Movement Alert|Arrowhead Pharmaceuticals Rises 19.25% in Regular Trading, Core Pipeline Plozasiran Achieves Key Late-Stage Trial Endpoints

Market Focus
·
Jul 22

Arrowhead Pharmaceuticals Shares up 18.1% Premarket After Blood-fat Drug Meets Late-stage Trial Goals

THOMSON REUTERS
·
Jul 22

Arrowhead Rises After Blood-fat Drug Meets Late-stage Trial Goals

Reuters
·
Jul 22

Movement Alert|Arrowhead Pharmaceuticals Rises 8.64% in Pre-Market Trading, Core Pipeline Plozasiran Delivers Strong Results Across Multiple Key Trials

Market Focus
·
Jul 22

Arrowhead Pharma Announces Press Release on Plozasiran Phase 3 Shasta-3 and Shasta-4 Topline Results

Reuters
·
Jul 22

Arrowhead Pharmaceuticals - Plozasiran Shows Significant Reduction in Acute Pancreatitis Events, 100% in High-risk Patients

THOMSON REUTERS
·
Jul 22

Arrowhead Pharmaceuticals - Plozasiran Demonstrates Consistent Safety Profile with no New Safety Signals

THOMSON REUTERS
·
Jul 22

Arrowhead Pharmaceuticals - Plozasiran Achieves 79% and 81% Median Triglyceride Reduction in Shasta-3 and Shasta-4

THOMSON REUTERS
·
Jul 22

Arrowhead Pharmaceuticals - to File Supplemental Nda for Plozasiran with U.S. FDA Before End of 2026

THOMSON REUTERS
·
Jul 22

Press Release: Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results

Dow Jones
·
Jul 21